Simvastatin-loaded liposome nanoparticles treatment for uterine leiomyoma in a patient-derived xenograft mouse model: a pilot study

• Published in: Journal of obstetrics and gynaecology Vol. 42; no. 6; p. 2139
• Main Authors: El Sabeh, Malak, Vincent, Kathleen L, Afrin, Sadia, Motamedi, Massoud, Saada, Jamal, Yang, Jinping, Ozpolat, Bulent, Kilic, Gokhan S, Borahay, Mostafa A
• Format: Journal Article
• Language: English
• Published: England 18.08.2022
• Subjects: Animals; Disease Models, Animal; Heterografts; Humans; Ki-67 Antigen; Leiomyoma - drug therapy; Leiomyoma - pathology; Liposomes; Mice; Nanoparticles; Pilot Projects; Simvastatin - pharmacology; simvastatin; Uterine leiomyoma; nanoparticles; animal model; fibroid
• ISSN: 1364-6893
• DOI: 10.1080/01443615.2022.2033964

Uterine leiomyomas are complex tumours with limited medical treatment options. Simvastatin is used to treat hypercholesterolaemia and has shown promising effects as a treatment option for leiomyomas. Previously, our group demonstrated a promising effect of simvastatin treatment in a patient-derived xenograft mouse model. Here, we tested the efficacy of simvastatin liposomal nanoparticles (NPs). After bilateral leiomyoma xenograft implantation, mice (N = 12) were divided into three treatment arms: control, simvastatin and simvastatin-loaded liposome NPs (simvastatin-NPs). Treatment with simvastatin significantly reduced tumour volume and inhibited the Ki67 expression when compared to the control group. There was a trend of reduced tumour volume and Ki67 expression after treatment with simvastatin-NP; however, the results were not significant. Due to low bioavailability and short half-life of simvastatin, liposomal NPs have the potential to enhance drug delivery, however, in this study NP did not provide improvement over simvastatin, but did demonstrate their potential for the delivery of simvastatin.Impact statement Simvastatin treatment in a patient-derived xenograft mouse model reduced tumour growth and decreased proliferation. Treatment with simvastatin significantly reduced tumour volume and inhibited the Ki67 expression when compared to the control group. There was a trend of reduced tumour volume and Ki67 expression after treatment with simvastatin-NP, however, it did not improve the efficacy of simvastatin at reducing tumour growth and proliferation. More studies are needed to optimise the formulation of NPs to further enhance the sustainable delivery of simvastatin.